JP2023536504A5 - - Google Patents

Info

Publication number
JP2023536504A5
JP2023536504A5 JP2023507923A JP2023507923A JP2023536504A5 JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5
Authority
JP
Japan
Application number
JP2023507923A
Other languages
Japanese (ja)
Other versions
JP2023536504A (ja
JPWO2022029617A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057089 external-priority patent/WO2022029617A1/en
Publication of JP2023536504A publication Critical patent/JP2023536504A/ja
Publication of JP2023536504A5 publication Critical patent/JP2023536504A5/ja
Publication of JPWO2022029617A5 publication Critical patent/JPWO2022029617A5/ja
Pending legal-status Critical Current

Links

JP2023507923A 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 Pending JP2023536504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (3)

Publication Number Publication Date
JP2023536504A JP2023536504A (ja) 2023-08-25
JP2023536504A5 true JP2023536504A5 (https=) 2024-08-09
JPWO2022029617A5 JPWO2022029617A5 (https=) 2024-08-09

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507923A Pending JP2023536504A (ja) 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Country Status (11)

Country Link
US (1) US12570650B2 (https=)
EP (1) EP4192835A4 (https=)
JP (1) JP2023536504A (https=)
KR (1) KR20230061349A (https=)
CN (1) CN116529250A (https=)
AU (1) AU2021320052A1 (https=)
BR (1) BR112023002089A2 (https=)
CA (1) CA3188024A1 (https=)
IL (1) IL300387A (https=)
MX (1) MX2023001445A (https=)
WO (1) WO2022029617A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited Irak4阻害剤としての置換インダゾール化合物
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017011371A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
US20190300521A1 (en) 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12371426B2 (en) 2018-04-26 2025-07-29 Aurigene Discovery Technologies Limited Pyridazine derivatives as SMARCA2/4 degraders
AU2021205326A1 (en) * 2020-01-10 2022-07-21 Amgen Inc. SMARCA2-VHL degraders

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2023536504A5 (https=)
JP2023510746A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021015566A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)